1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Boehringer/Zealand Dual Agonist Achieves Promising Level Of Weight Loss

Drug Targets GLP-1 And Glucagon Receptors

 
• By Mandy Jackson

Survodutide provides another obesity treatment option, albeit with gastrointestinal side effects that will need to be managed with slow titration to maintenance dosing, which will be tested in Phase III.

Jeans with a tape measure as a belt
Survodutide Achieved Up To 18.7% Weight Loss At 46 Weeks • Source: Shutterstock

Data for the Boehringer Ingelheim GmbH/Zealand Pharma A/S drug candidate survodutide (BI 456906) presented at the American Diabetes Association (ADA) annual meeting in San Diego showed that at the highest dose of 4.8mg once weekly, patients who were overweight or obese and who remained on treatment for the full 46 weeks of the companies’ Phase II clinical trial achieved 18.7% weight loss, potentially offering an additional option for doctors prescribing GLP-1-targeting medicines.

Unlike Novo Nordisk A/S’s US Food and Drug Administration-approved GLP-1 agonist Wegovy (semaglutide) for obesity and Eli Lilly and Company’s GLP-1/GIP agonist Mounjaro (tirzepatide), which is approved for type 2 diabetes and may receive FDA approval for obesity before the end of 2023, survodutide is an agonist of GLP-1 and the glucagon receptor (GCGR). Boehringer and Zealand reported topline results for their dual agonist in May for all patients treated in their Phase II trial, including those who did not complete the trial, and weight loss was 14.9%

More from Clinical Trials

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

More from R&D